Tvardi Therapeutics Inc. (TVRD), a clinical-stage biopharmaceutical company developing oral therapies for ?brosis-driven diseases, has a clinical trial catalyst to watch in the fourth quarter of this year.The company's lead drug candidate is TTI-101, an oral inhibitor of STAT3 (signal transducer and activator of transcription 3), a protein that plays a key role in cancer and fibrosis. TTI-101 is b...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.